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Colon cancer represents a malignancy with a high inci-
dence and mortality throughout the world, its etiology
involving many genetic, immunological and biochemical
factors. Anti-cancer drugs might exert their action during
physiological pathways of apoptosis, leading to tumour cell
destruction. One of the most effective anti-cancer agents
used in the treatment of colorectal cancers is 5-fluoroura-
cyl (5-FU), but tumour chemoresistance is a major limiting
factor of its use. The purpose of this study was to assess
whether different doses of plant bioactive compounds as
genistein (GST) or resveratrol (RSV) might increase the
anti-carcinogenic and anti-proliferative effects of 5-FU
treatment and modulate gene vs. antigen expression of
molecules involved in cell proliferation and apoptosis
(P53, Bcl-2, Bax, Mdm2, PTEN) in colon tumour cell lines
(LoVo).
The compound-mediated cytotoxity was measured by
real-time cell analysis (RTCA) using xCELLigence System,
a cell-based label-free platform technology that utilises the
inherent morphological and adhesive characteristics of
the cell. DNA progression through cell cycle phases was
estimated by using PI staining (BD Cycletest Plus/DNA
Reagent kit), while apoptosis was assessed by Annexin-V/
FITC and PI double staining. In addition, antigen expres-
sion was evaluated by indirect immunofluorescence fol-
lowed by flow-cytometry acquisition and analysis by FACS
Canto II flow-cytometer. Gene expression was measured
by qRT-PCR using Applied Biosystems® 7300 System.
Both GST and RSV single treatments, or combined
with 5-FU induced a decrease of S% cell cycle phase, and
an increse of apoptotic events. Different concentrations
of GST or RSV blocked the treated cells in G2M; cells
treated with RSV and 5-FU were blocked in G0G1 phase,
while combined treatments with GST and 5-FU blocked
the cells in G2M phase. The gene and antigen expression
of molecules associated to cell proliferation and apoptosis
were modulated by single and combined treatments, and
additive effects of RSV or GST to 5-FU treatment were
observed.
The chemo-preventive efficacy has been associated to
enhanced apoptosis, therefore any therapeutic strategy that
specifically triggers apoptosis in cancer cells might have
potential immunotherapeutic value. By combining flavo-
noids with anti-cancer drugs, an increase of the antitumoral
effects might be achieved, specifically in highly invasive
cancer cells, while in non-tumoral cells the cytotoxic side
effects could be reduced.
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